Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.31 and last traded at $15.12, with a volume of 2903073 shares traded. The stock had previously closed at $15.16.
Takeda Pharmaceutical Stock Down 0.5 %
The business has a 50-day moving average of $14.12 and a 200 day moving average of $13.93. The company has a market capitalization of $47.94 billion, a PE ratio of 37.69, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.
Institutional Investors Weigh In On Takeda Pharmaceutical
A number of hedge funds have recently bought and sold shares of the business. Versant Capital Management Inc bought a new stake in shares of Takeda Pharmaceutical in the 4th quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical during the third quarter worth approximately $40,000. BNP Paribas Financial Markets increased its stake in Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock worth $46,000 after acquiring an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC raised its position in Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock valued at $47,000 after purchasing an additional 1,976 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 9.17% of the company's stock.
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Further Reading
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
